CEO Martin Vidaeus presented (ENG) at the investor forum Småbolagsdagen held at the Sheraton Hotel in Stockholm, Sweden by the investor relations firm Aktiespararna on June 11, 2018. There were over 300 people in attendance, while 3,700 connected live via the internet to watch and listen to the 57 publicly-traded companies from Scandinavia.
For more information, contact:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on the Spotlight Stockmarket, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com